Lorlatinib found to be safe and effective for patients with ALK-driven relapsed/refractory high-risk neuroblastoma
In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children's Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma ...
Apr 3, 2023
0
21